X0508 4 2026-02-27 true 0001599901 Avidity Biosciences, Inc. RNAM 0001841990 Flanagan W. Michael C/O AVIDITY BIOSCIENCES, INC. 3020 CALLAN RD. SAN DIEGO CA 92121 false true false false Chief Scientific Officer false Common Stock 2026-02-27 4 D false 150365 D 0 D Stock Option (Right to Buy) 26.75 2026-02-27 4 D false 25000 D 2031-01-20 Common Stock 25000 0 D Stock Option (Right to Buy) 14.22 2026-02-27 4 D false 66500 D 2032-01-20 Common Stock 66500 0 D Stock Option (Right to Buy) 22.47 2026-02-27 4 D false 96000 D 2033-01-19 Common Stock 96000 0 D Stock Option (Right to Buy) 6.57 2026-02-27 4 D false 72000 D 2033-09-10 Common Stock 72000 0 D Stock Option (Right to Buy) 10.16 2026-02-27 4 D false 88000 D 2034-01-19 Common Stock 88000 0 D Stock Option (Right to Buy) 31.42 2026-02-27 4 D false 50000 D 2035-01-05 Common Stock 50000 0 D The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 2026-02-27